morusin and Liver-Neoplasms

morusin has been researched along with Liver-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for morusin and Liver-Neoplasms

Article	Year
Antitumor Effect of Morusin via G1 Arrest and Antiglycolysis by AMPK Activation in Hepatocellular Cancer. International journal of molecular sciences, 2021, Sep-30, Volume: 22, Issue:19 Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Survival; Flavonoids; G1 Phase Cell Cycle Checkpoints; Glycolysis; Hexokinase; Humans; Lactate Dehydrogenase 5; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Morus; Plant Extracts; Plant Roots; Thyroid Hormone-Binding Proteins; Thyroid Hormones; TOR Serine-Threonine Kinases	2021
Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition. Drug design, development and therapy, 2017, Volume: 11 Hepatocellular carcinoma (HCC) is one of the most aggressive cancers with high mortality worldwide. Research and development of novel agents for HCC therapy is in demand, urgently. Morusin has been reported to exhibit potential cytotoxic activity in several cancer cell lines. However, whether it has potential antiangiogenic activity especially in HCC remains unclear. In the current study, we found that morusin exerted growth inhibition effects on human HCC cells (HepG2 and Hep3B) in vitro and human HCC cell (HepG2) xenografts in vivo. Moreover, apoptosis induction was observed in a dose-dependent manner after morusin treatment along with an increase in the expression of active caspase-3 and the Bax/Bcl-2 expression ratio. More importantly, morusin inhibited proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro and downregulated angiogenic proteins in HCC cells and HUVECs. In vivo, tumor angiogenesis was also attenuated after morusin treatment. In addition, morusin suppressed constitutive as well as IL-6-induced STAT3 phosphorylation in HCC cells and corresponding tumor tissues. Overall, morusin has a potential anticancer effect on human HCC cells in vitro and in vivo by inducing apoptosis and inhibiting anti-angiogenesis. The corresponding mechanism might be associated with the attenuation of the IL-6/STAT3 signaling pathway. Morusin might serve as a promising novel anticancer agent in HCC therapy, and requires further study. Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Flavonoids; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-6; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; STAT3 Transcription Factor; Tumor Stem Cell Assay	2017

Article

Year

Antitumor Effect of Morusin via G1 Arrest and Antiglycolysis by AMPK Activation in Hepatocellular Cancer.

International journal of molecular sciences, 2021, Sep-30, Volume: 22, Issue:19

Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Cell Survival; Flavonoids; G1 Phase Cell Cycle Checkpoints; Glycolysis; Hexokinase; Humans; Lactate Dehydrogenase 5; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Morus; Plant Extracts; Plant Roots; Thyroid Hormone-Binding Proteins; Thyroid Hormones; TOR Serine-Threonine Kinases

2021

Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibition.

Drug design, development and therapy, 2017, Volume: 11

Hepatocellular carcinoma (HCC) is one of the most aggressive cancers with high mortality worldwide. Research and development of novel agents for HCC therapy is in demand, urgently. Morusin has been reported to exhibit potential cytotoxic activity in several cancer cell lines. However, whether it has potential antiangiogenic activity especially in HCC remains unclear. In the current study, we found that morusin exerted growth inhibition effects on human HCC cells (HepG2 and Hep3B) in vitro and human HCC cell (HepG2) xenografts in vivo. Moreover, apoptosis induction was observed in a dose-dependent manner after morusin treatment along with an increase in the expression of active caspase-3 and the Bax/Bcl-2 expression ratio. More importantly, morusin inhibited proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) in vitro and downregulated angiogenic proteins in HCC cells and HUVECs. In vivo, tumor angiogenesis was also attenuated after morusin treatment. In addition, morusin suppressed constitutive as well as IL-6-induced STAT3 phosphorylation in HCC cells and corresponding tumor tissues. Overall, morusin has a potential anticancer effect on human HCC cells in vitro and in vivo by inducing apoptosis and inhibiting anti-angiogenesis. The corresponding mechanism might be associated with the attenuation of the IL-6/STAT3 signaling pathway. Morusin might serve as a promising novel anticancer agent in HCC therapy, and requires further study.

Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Flavonoids; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-6; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; STAT3 Transcription Factor; Tumor Stem Cell Assay

2017